Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series (Q40335671)

From Wikidata

Jump to navigation Jump to search

scientific article published on February 2011

Language	Label	Description	Also known as
English	Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series	scientific article published on February 2011

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series (English)

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

multicenter clinical trial

0 references

juvenile rheumatoid arthritis

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Mary Beth F Son

15

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Norman T Ilowite

object named as

Norman T Ilowite

18

0 references

Randy Quentin Cron

object named as

Randy Q Cron

19

0 references

author name string

Peter A Nigrovic

1

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Melissa Mannion

2

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Femke H M Prince

3

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Andrew Zeft

4

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

C Egla Rabinovich

5

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Marion A J van Rossum

6

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Elisabetta Cortis

7

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Manuela Pardeo

8

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Paivi M Miettunen

9

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Ginger Janow

10

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

James Birmingham

11

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Aaron Eggebeen

12

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Erin Janssen

13

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Andrew I Shulman

14

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Sandy Hong

16

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Karla Jones

17

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Gloria C Higgins

20

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

publication date

1 February 2011

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Arthritis & Rheumatology

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

63

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

545-555

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.30128

21 January 2018

Clinical remission in patients with systemic juvenile idiopathic arthritis treated with anti-tumor necrosis factor agents.

1 reference

https://api.crossref.org/works/10.1002%2FART.30128

21 January 2018

Predictors of disease course and remission in systemic juvenile idiopathic arthritis: significance of early clinical and laboratory features

1 reference

https://api.crossref.org/works/10.1002%2FART.30128

21 January 2018

Long-term follow-up of 246 adults with juvenile idiopathic arthritis: functional outcome

1 reference

https://api.crossref.org/works/10.1002%2FART.30128

21 January 2018

Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade

1 reference

https://api.crossref.org/works/10.1002%2FART.30128

21 January 2018

The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.30128

21 January 2018

Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France

1 reference

https://api.crossref.org/works/10.1002%2FART.30128

21 January 2018

Anakinra for systemic juvenile arthritis: the Rocky Mountain experience

1 reference

https://api.crossref.org/works/10.1002%2FART.30128

21 January 2018

Does systemic-onset juvenile idiopathic arthritis belong under juvenile idiopathic arthritis?

1 reference

https://api.crossref.org/works/10.1002%2FART.30128

21 January 2018

Acute hepatitis in three patients with systemic juvenile idiopathic arthritis taking interleukin-1 receptor antagonist

1 reference

https://api.crossref.org/works/10.1002%2FART.30128

21 January 2018

Coronary artery dilation among patients presenting with systemic-onset juvenile idiopathic arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.30128

21 January 2018

Juvenile Rheumatoid Arthritis: A general review and report of 100 patients observed for 15 years

1 reference

https://api.crossref.org/works/10.1002%2FART.30128

21 January 2018

Early predictors of poor functional outcome in systemic-onset juvenile rheumatoid arthritis: a multicenter cohort study

1 reference

https://api.crossref.org/works/10.1002%2FART.30128

21 January 2018

Early outcomes and improvement of patients with juvenile idiopathic arthritis enrolled in a Canadian multicenter inception cohort

1 reference

https://api.crossref.org/works/10.1002%2FART.30128

21 January 2018

Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study.

1 reference

https://api.crossref.org/works/10.1002%2FART.30128

21 January 2018

Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome

1 reference

https://api.crossref.org/works/10.1002%2FART.30128

21 January 2018

Induction of cartilage damage by overexpression of T cell interleukin-17A in experimental arthritis in mice deficient in interleukin-1.

1 reference

https://api.crossref.org/works/10.1002%2FART.30128

21 January 2018

Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1002%2FART.30128

21 January 2018

Recent developments in anti-rheumatic drugs in pediatrics: treatment of juvenile idiopathic arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.30128

21 January 2018

Identifiers

10.1002/ART.30128

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40335671&oldid=1895560689"